Breaking News

Shuttle Pharmaceuticals Completes Manufacturing of API for Clinical Trial

TCG GreenChem successfully completes initial manufacturing campaign for the API of Ropidoxuridine for use in Phase II trial in brain cancer.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company, reported that TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the company’s upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. Shuttle’s recent request for a Type B pre-IND meeting with the FDA on the proposed Phase II clinical trial ha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters